Molecular marker predicts patients most likely to benefit longest from two popular cancer drugs
Thursday, September 5, 2013 - 14:30
in Health & Medicine
Scientists have identified a molecular marker called “Mig 6” that appears to accurately predict longer survival -- up to two years -- among patients prescribed two of the most widely used drugs in a class of anticancer agents called EGFR inhibitors.